Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Oncotarget. 2021 Oct 12;12(21):2231. doi: 10.18632/oncotarget.28012.

Authors

Joshua E Allen¹, C Leah B Kline², Varun V Prabhu¹, Jessica Wagner², Jo Ishizawa³, Neel Madhukar⁴, Avital Lev², Marie Baumeister², Lanlan Zhou², Amriti Lulla², Martin Stogniew¹, Lee Schalop¹, Cyril Benes^{5

6}, Howard L Kaufman⁷, Richard S Pottorf⁸, B Rao Nallaganchu⁸, Gary L Olson⁸, Fahd Al-Mulla⁹, Madeleine Duvic³, Gen Sheng Wu¹⁰, David T Dicker², Mala K Talekar¹¹, Bora Lim³, Olivier Elemento⁴, Wolfgang Oster¹, Joseph Bertino⁷, Keith Flaherty^{5

6}, Michael L Wang³, Gautam Borthakur³, Michael Andreeff³, Mark Stein⁷, Wafik S El-Deiry²

Affiliations

¹ Oncoceutics, Inc., Philadelphia, PA, USA.
² Fox Chase Cancer Center, Philadelphia, PA, USA.
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Weill Cornell Medicine, New York, NY, USA.
⁵ Massachusetts General Hospital, Boston, MA, USA.
⁶ Harvard Medical School, Boston, MA, USA.
⁷ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
⁸ Provid Pharmaceuticals, Monmouth Junction, NJ, USA.
⁹ Kuwait University Medical School, Kuwait.
¹⁰ Karmanos Cancer Institute, Detroit, MI, USA.
¹¹ The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.11814.].

Copyright: © 2021 Allen et al.

Publication types

Published Erratum